Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.

Autor: Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam., Blommestein HM; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam., Coupé VMH; Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam., Hendriks MP; Department of Internal Medicine, Northwest Clinics, Alkmaar., Kruit WHJ; Department for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam., Plaisier PW; Department of Surgical Oncology, Albert Schweitzer Hospital, Dordrecht., van Ruth S; Department of Dermatology, Tergooi, Hilversum., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda., Wouters MWJM; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam., Franken MG; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands., Uyl-de Groot CA; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Publikováno v: Melanoma research [Melanoma Res] 2021 Jun 01; Vol. 31 (3), pp. 249-257.

Impact of Adjuvant Interferon Therapy on Survival Outcomes for Cutaneous Melanoma With Parotid Involvement.

Autor: Kim E; University of Michigan Medical School, Ann Arbor, Michigan, U.S.A., Raven SA; Department of Otolaryngology-Head & Neck Surgery, Wayne State University, Detroit, Michigan, U.S.A., Lenze NR; Department of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A., Farlow JL; Department of Otolaryngology-Head & Neck Surgery, Indiana University, Indianapolis, Indiana, U.S.A., McLean SA; Department of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.

Publikováno v: The Laryngoscope [Laryngoscope] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Autor: Jochems A; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands. a.jochems@lumc.nl.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands. a.jochems@lumc.nl., van der Kooij MK; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands., Fiocco M; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Mathematical Institute Leiden University, Niels Bohrweg 1, 2333 CA Leiden, The Netherlands., Schouwenburg MG; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands., Aarts MJ; Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands., van Akkooi AC; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre, 6130 MB Sittard-Geleen, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, VU Medical Centre, de Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands., Franken MG; Department of Health Technology Assessment, Institute for Medical Technology Assessment and Erasmus School of Health Policy & Management, Erasmus University, Burgemeester Oudlaan 50, 3000 DR Rotterdam, The Netherlands., de Groot JB; Department of Medical Oncology, Isala Oncological Center, 8000 GK Zwolle, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Koornstra RH; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands., Kruit WHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Molewaterplein 40, 3000 CA Rotterdam, The Netherlands., Louwman M; Netherlands Comprehensive Cancer Organisation, PO Box 19079, 3501 DB Utrecht, The Netherlands., Piersma D; Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands., van Rijn RS; Department of Medical Oncology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Ten Tije AJ; Department of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV Breda, The Netherlands., Vreugdenhil G; Department of Medical Oncology, Maxima Medisch Centrum, de Run 4600, 5500 MB Veldhoven, The Netherlands., Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., van Zeijl MCT; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands., van der Hoeven KJM; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2019 Jul 18; Vol. 11 (7). Date of Electronic Publication: 2019 Jul 18.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Autor: Dreno B; Department of Dermatooncology, Hotel Dieu Nantes University Hospital, Nantes, France., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Smithers BM; Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia., Santinami M; Melanoma Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Jouary T; Service d'Oncologie Médicale, Hôpital François Mitterrand, Pau, France., Gutzmer R; Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany., Levchenko E; Petrov Research Institute of Oncology, St Petersburg, Russia., Rutkowski P; Department of Soft Tissue, Bone Sarcoma, and Melanoma, Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland., Grob JJ; Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France., Korovin S; Department of Skin and Soft Tissue Tumours, National Cancer Institute, Kiev, Ukraine., Drucis K; Swissmed Centrum Zdrowia, Gdansk, Poland; Department of Surgical Oncology, Gdansk Medical University, Gdansk, Poland., Grange F; Dermatology Department, Hôpital Robert Debré, Université de Reims Champagne-Ardenne, Reims, France., Machet L; Department of Dermatology, Centre Hospitalier Universitaire, Tours, France; UFR de Médecine, Université François-Rabelais, Tours, France., Hersey P; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia., Krajsova I; Dermato-oncology Department, General University Hospital, Prague, Czech Republic., Testori A; Columbus Clinic Center, Milan, Italy., Conry R; Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Guillot B; Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital Saint-Éloi, Montpellier, France., Kruit WHJ; Department of Medical Oncology, Erasmus MC Cancer institute, Rotterdam, Netherlands., Demidov L; Cancer Research Center, Moscow, Russia., Thompson JA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Bondarenko I; Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine., Jaroszek J; Centrum Medyczne Bieńkowski, Klinika Chirurgii Plastycznej, Bydgoszcz, Poland; Department of Oncological Surgery, Oncology Center, Bydgoszcz, Poland., Puig S; Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain., Cinat G; Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina., Hauschild A; Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany., Goeman JJ; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands., van Houwelingen HC; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands., Ulloa-Montoya F; GlaxoSmithKline, Rixensart, Belgium. Electronic address: fernando.x.ulloa-montoya@GSK.com., Callegaro A; GlaxoSmithKline, Rixensart, Belgium., Dizier B; GlaxoSmithKline, Rixensart, Belgium; Immunology Translational Medicine, UCB, Brussels, Belgium., Spiessens B; GlaxoSmithKline, Rixensart, Belgium; Biostatistics Department, Janssen Research & Development, Beerse, Belgium., Debois M; GlaxoSmithKline, Rixensart, Belgium., Brichard VG; GlaxoSmithKline, Rixensart, Belgium; ViaNova Biosciences, Brussels, Belgium., Louahed J; GlaxoSmithKline, Rixensart, Belgium., Therasse P; GlaxoSmithKline, Rixensart, Belgium; Laboratoires Servier, Paris, France., Debruyne C; GlaxoSmithKline, Rixensart, Belgium; University Hospitals Leuven, Leuven, Belgium., Kirkwood JM; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2018 Jul; Vol. 19 (7), pp. 916-929. Date of Electronic Publication: 2018 Jun 13.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Autor: Jochems A; Department of Medical Oncology, Leiden University Medical Center.; Dutch Institute for Clinical Auditing, Leiden., Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management., Franken MG; Institute for Medical Technology Assessment, Erasmus University Rotterdam., Schouwenburg MG; Department of Medical Oncology, Leiden University Medical Center.; Dutch Institute for Clinical Auditing, Leiden., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht., van Akkooi ACJ; Departments of Surgical Oncology., van den Berkmortel FWPJ; Department of Internal Medicine, Zuyderland Medical Center Geleen, Heerlen., van den Eertwegh AJM; Dutch Institute for Clinical Auditing, Leiden.; Department of Medical Oncology, VU University Medical Center, Amsterdam., Groenewegen G; Department of Medical Oncology, University Medical Center Utrecht., de Groot JWB; Department of Medical Oncology, Isala, Zwolle., Haanen JBAG; Dutch Institute for Clinical Auditing, Leiden.; Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Groningen., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center., Koornstra RH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen., Kruit WHJ; Department for Medical Oncology, Erasmus MC Cancer Institute, Rotterdam., Louwman MWJ; Netherlands Comprehensive Cancer Organisation, Utrecht., Piersma D; Department of Internal Medicine, Medical Spectrum Twente, Enschede., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Breda., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands., Wouters MWJM; Dutch Institute for Clinical Auditing, Leiden.; Departments of Surgical Oncology., Uyl-de Groot CA; Department of Health Technology Assessment, Erasmus School of Health Policy & Management.; Institute for Medical Technology Assessment, Erasmus University Rotterdam., van der Hoeven KJM; Dutch Institute for Clinical Auditing, Leiden.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2018 Jul; Vol. 29 (6), pp. 572-578.